Shares of iBio, Inc. (NYSE:IBIO – Get Free Report) traded up 2.5% on Wednesday . The company traded as high as $2.44 and last traded at $2.42. 57,343 shares traded hands during trading, a decline of 95% from the average session volume of 1,064,661 shares. The stock had previously closed at $2.36.
iBio Price Performance
The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.37 and a current ratio of 3.37. The stock has a 50 day simple moving average of $2.60 and a 200-day simple moving average of $2.27.
iBio (NYSE:IBIO – Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.46). As a group, research analysts anticipate that iBio, Inc. will post -1.74 EPS for the current year.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Further Reading
- Five stocks we like better than iBio
- What Are Some of the Best Large-Cap Stocks to Buy?
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- Consumer Discretionary Stocks Explained
- 2 Drone Stocks Surging from Increased Media Attention
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
